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EgyptAbstract Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease
with complex genetic inheritance. Many reports have provided evidence that signal transducer
and activator of transcription-4 (STAT4) may participate in the pathogenesis of SLE.
Aim of the work: The aim was to investigate the clinical signiﬁcance and possible association of
STAT4 (G/T) genetic polymorphism and the susceptibility to SLE in a cohort of Egyptian female
patients.
Patients and methods: Sixty-ﬁve Egyptian SLE female patients and 100 age and sex-matched
unrelated female healthy blood donors who served as controls, were included in the study. STAT4
genotyping was performed by real time PCR-allelic discrimination technique.
Results: STAT4 genotyping in patients revealed that 63.1% had GG, 32.3% GT and 6.15% wild
(TT) genotype. There was a non-signiﬁcant difference in the distribution of STAT4 genotypes
between patients and controls. Vasculitis, photosensitivity and lupus nephritis were signiﬁcantly
increased in patients with the homomutant (GG and TT) compared to heteromutant (GT) genotype
(p= 0.01, p= 0.04 and p< 0.01 respectively). Patients with a TT genotype had a signiﬁcantly con-
sumed C3 and C4 levels and higher anti-dsDNA positivity compared to those with GG and GT
genotypes. Promoter polymorphism tended to be higher in juvenile-onset SLE cases.
Conclusions: STAT4 (G/T) polymorphism was not associated with an increased risk of SLE in
Egyptian females. However, vasculitis, photosensitivity and renal involvement were signiﬁcantly
higher among patients harboring the homomutant genotypes. Genetic polymorphism may be an
important determinant affecting disease progression and is associated with DNA positivity and
younger age of onset.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease with involvement of different body systems and the
development of an immune response against self-antigens,
leading to tissue inﬂammation, destruction and even end-organ
damage [1]. SLE is more prevalent in females compared to
males (9:1) and in African-American (AA), Asian (AS) and
Hispanic (HI) populations compared to European (EA) [2,3].
There are also marked disparities in SLE incidence and preva-
lence worldwide; varying among different ethnic and geo-
graphical populations [4]. SLE is four times more common
in people of African-American ancestry than those of Euro-
pean ancestry [5]. In addition, African-Americans have a
markedly increased risk for developing lupus nephritis relative
to European-Americans [6].
The etiology of SLE is not clearly understood, but genetic
factors likely inﬂuence the pathogenesis, disease expression,
and production of auto antibodies [7]. Environmental factors
together with genetic components are involved in the abnormal
immune responses and in the pathogenesis of SLE. SLE ﬂare-
ups in response to various environmental components, such as
exposure to ultraviolet light, certain drugs, chemicals, and viral
infections are documented [8]. In SLE, there is loss of tolerance
to self-antigens with polyclonal activation of B lymphocytes,
production of different auto-antibodies, and an altered func-
tion of T cells with alterations in cytokine biosynthesis [9].
Numerous susceptibility genes for SLE have been reported in
candidate gene and genome wide association (GWA) studies;
moreover, some of these genes have been conﬁrmed to have
some association among distinct populations [10]. The com-
plexity of etiology and pathogenesis in SLE, enclosing genetic
and environmental factors, apparently is one of the greatest
challenges for both researchers and clinicians [11]. By partici-
pating in transcription complex with other co-factors, STAT4
harbors the potential of regulating a large number of target
genes, which may contribute to their strong association with
SLE [12].
The discovery of the link between the INF-a activation
pathway and SLE has greatly contributed to a better under-
standing of pathogenesis of SLE [13] variants of certain
INF-a pathway genes, including IRF5, IRF7, signal trans-
ducer and activator of transcription (STAT4), and tyrosine
kinase2 have been associated with SLE susceptibility in many
ethnic groups, but the complete impact of genetic variation on
pathway activation is not fully understood [14,15]. STAT4 is a
transcription factor that is expressed in the activated periphe-
ral blood monocytes, dendritic cells and macrophages at the
sites of inﬂammation in humans [16]. It encodes transcription
factor that mediates the effect of several cytokines, including
interleukin-12 (IL-12), INF-a, and IL-23, in T-cell and mono-
cytes, TH1 and TH17 differentiation, monocyte activation and
interferon gamma production [17,18], all playing a role in
chronic inﬂammatory disorders, which means a possible cru-
cial role of STAT4 in the development of autoimmune diseases
such as SLE [19].
Previous studies have provided evidence that STAT4 may
participate in the pathogenesis of SLE, while studies of rela-
tion between this gene and genetic susceptibility to subpheno-
types of SLE were seldom observed [15]. The aim of current
work was to investigate the possible role of STAT4(rs7576485) G/T gene polymorphism as a molecular risk factor
for the development of SLE and its possible association with
certain clinical or laboratory characteristics of the disease in
a cohort of Egyptian females.2. Patients and methods
2.1. Study population
The current case–control study was conducted on sixty-ﬁve
Egyptian SLE female patients diagnosed according to Systemic
Lupus International Collaborating Clinics classiﬁcation criteria
for SLE [20]. All patients were attending the Rheumatology
and Rehabilitation department, Faculty of medicine, Cairo
University. Also, one hundred age and sex-matched unrelated
female healthy blood donors were included in the study as a
control group. Patients were subjected to a thorough clinical
examination and information with regard to clinical manifesta-
tions of patients was obtained (age, malar rash, discoid lesions,
photosensitivity, oral ulcers, arthritis, and renal, neurological
and hematological disorder). On the day of sampling, labora-
tory assessment was done in the form of complete hemogram,
erythrocyte sedimentation rate (ESR), serum complement level
(C3 and C4), serum antinuclear antibodies (ANA) and anti-
double stranded deoxyribonucleic acid (ds-DNA) antibodies
by indirect immune-ﬂuorescence, complete urine analysis and
kidney function tests. LN was deﬁned as clinical and laboratory
manifestations that meet ACR criteria (persistent protein-
uria > 0.5 g per day or greater than +++ by dipstick, and/
or cellular casts including red blood cells [RBCs], hemoglobin,
granular, tubular, or mixed) and/or a renal biopsy sample dem-
onstrating immune complex–mediated glomerulonephritis
compatible with LN [20]. Lupus disease activities were assessed
using SLE disease activity index (SLEDAI) score [21]. The
results of renal biopsy grading from patients with nephritis
were retrospectively obtained from patients’ medical records.
The protocol for this research conforms to the provisions of
the World Medical Association’s Declaration of Helsinki.
Informed Consent was obtained from all participants prior
to the study. Approval from our institutional scientiﬁc and
ethics committee was also obtained.2.2. Genotyping of STAT4 (rs7574865) by real time PCR based
allelic discrimination assay
For all participants, genomic DNA was extracted from periph-
eral blood leukocytes using a QIA Amp DNA Minikit (Qia-
gen, Germany) according to the manufacturer’s instructions.
Identiﬁcation of the STAT4G/T (rs7574865) polymorphic var-
iant was performed by real time polymerase chain reaction
using allelic discrimination (AD) assay; a multiplexed end
point assay that detects variants of a single nucleic acid
sequence using two primer/probe pairs in each reaction allow-
ing genotyping of the two possible variants at the single-
nucleic polymorphism (SNP) site in a target template sequence
using a speciﬁc, ﬂuorescent, dye-labeled probe for each allele.
Probes contained different ﬂuorescent reporter dyes (FAM
and VIC). Primers and probes were purchased from Applied
Biosystems (PN: 4351379, USA) as a commercially complete
kit prepared by the company. Allelic discrimination assay
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PCR System. For quality control, genotyping was repeated
blindedly with respect to case/control status to conﬁrm our
results for 30 samples and were 100% concordant.
Statistical analysis: Data were analyzed using SPSS statisti-
cal package version 17. For numerical data, parametric data
were expressed as mean, standard deviation and range, while
non-parametric data were expressed as median and interquar-
tile range. Qualitative data were expressed as frequency and
percentage. Chi-square test or Fisher’s exact test was used to
examine the relation between qualitative variables. Non-para-
metric numerical data were analyzed using Mann–Whitney
test. Correlation analysis was performed by Spearman’s rank
correlation. Unconditional logistic regression analysis was
used to calculate odds ratios (OR) and 95% conﬁdence inter-
vals (CI) for risk estimation. P-value less than 0.05 was consid-
ered signiﬁcant. Chi-square (v2) test was performed to assess
deviation from Hardy–Weinberg equilibrium in controls.
3. Results
The study included 65 female SLE patients with a mean age of
29.22 ± 9.01 years (10–50 years). There were 8 patients with
juvenile-onset and 57 adult-onset SLE cases. One hundred
age-matched unrelated female healthy blood donors were
included in the study as a control group, their mean age was
30.11 ± 9.41 years. The frequencies of STAT4 genotypes in
SLE patients and controls are presented in Table 1. Also, the
age, clinical manifestations, laboratory investigations, renal
biopsy class and disease activity grades among the three
STAT4 genotypes in SLE patients are shown in Table 2.
Vasculitis and photosensitivity were signiﬁcantly higher in
patients with the homomutant STAT4 genotype (GG and
TT) compared to those with the heteromutant genotype
(GT) (p= 0.01 and p= 0.04 respectively). Regarding renal
involvement, the incidence of lupus nephritis was signiﬁcantly
higher in patients with the homomutant genotype (75%) than
those with the heteromutant genotype (25%) (p< 0.01).
The TLC was signiﬁcantly lower in SLE patients with the
GT genotype compared to the count in those with GG geno-
type (p= 0.02). The C3 and C4 levels in SLE patients with
the TT genotype were signiﬁcantly consumed compared to
those with GG (p< 0.0001 and p= 0.009) and GT
(p= 0.001 and 0.03) genotypes. Those with the TT genotype
had a signiﬁcantly higher anti-ds DNA positivity compared
to those with GG (p= 0.001) and GT (p= 0.04) genotypes.
The STAT4 genotype in the juvenile onset SLE cases
(n= 8) was GG in 3 (37.5%), GT in 4(50%) and TT in 1
(12.5%). Fifty-seven were adult onset SLE cases with a STAT4Table 1 Frequencies of STAT4 genotypes in SLE patients
and controls.
STAT4
n (%)
SLE patients
(n= 65)
Controls
(n= 100)
GG 40 (61.5) 68 (68)
GT 21 (32.3) 27 (27)
TT 4 (6.2) 5 (5)
STAT4: signal transducer and activator of transcription 4; SLE:
systemic lupus erythematosus.genotype of GG in 37 (64.9%), GT in 17 (29.8%) and TT in 3
(5.3%). There were no signiﬁcant differences between patients
according to disease onset as regards the clinical and labora-
tory manifestations or SLEDAI. Only 2 patients with a GG
genotype had a positive family history of SLE.
4. Discussion
Systemic lupus erythematosus is a complex autoimmune dis-
ease characterized by autoantibody production and organ
damage in which environmental factors together with genetic
components are involved in the abnormal immune responses
and in its pathogenesis [7]. The ethnic and genetic heterogene-
ity of SLE may contribute to the diversity of its clinical char-
acteristics. Genome-wide association (GWA) and candidate
gene studies have identiﬁed more than 30 common SLE risk
alleles in European and Asian derived populations [10,22].
The contribution of single nucleotide polymorphisms (SNPs)
of STAT4 G/C (rs7582694) and G/T (rs7574865) to the
incidence of SLE and its clinical manifestations has been
demonstrated [15,23].
The current study is an age-gender-ethnic-matched case–
control study, that aimed at investigating the impact of STAT4
G/T (rs7574865) genetic polymorphism on the susceptibility to
SLE and its possible association with certain clinical or labora-
tory characteristics of the disease in Egyptian females. This
study included 65 female SLE patients and 100 healthy female
volunteers. STAT4 genotyping was performed by real time
PCR-allelic discrimination technique.
Regarding STAT4 genotyping in SLE patients, 32.3% were
heterozygous harboring the GT genotype and 6.2% were
Homozygous having the TT genotype. The frequency of
STAT4 polymorphic genotypes was nearly similar to that
reported in Polish population being 37% and 11% for the
GT and TT genotypes [24]. However, In Northern Han Chi-
nese population [25] it was 48.1% and 17.0% for GT and
TT genotypes, and in a Japanese cohort it was 55.5% and
18.5% for GT and TT genotypes respectively [26].
In our study, there was no statistically signiﬁcant difference
found on comparing the frequency of STAT4 genotypes in
SLE patients and controls. Although our results are in accor-
dance with those of Zervou et al. [27] in a Turkish population,
they are contradictory to those reported in studies from Japa-
nese [26] and Chinese populations [25,28]. Luan and colleagues
[15] reported that STAT4 was a common and critical suscepti-
bility gene involved in the SLE pathogenesis in female Chinese.
STAT4 (rs7574865) has also been conﬁrmed as a genetic risk
factor for SLE in Colombians, Mexicans and Argentinean
cohorts [14]. This could be attributed to the ethnic difference
between the studied populations, in addition to the different
sample size of these studies. As SLE has a complex genetic
background, none of the genes is likely to be entirely responsi-
ble for triggering autoimmune response in SLE even if they
present potentially novel molecular mechanisms in the patho-
genesis of the disease [11].
Study of the inﬂuence of STAT4 (G/T) genetic polymor-
phism on the clinical and pathological characteristics of the
disease revealed that vasculitis and photosensitivity were sig-
niﬁcantly higher in SLE patients with the homomutant STAT4
genotype (GG and TT) compared to heteromutant (GT) ones.
Moreover, the incidence of lupus nephritis was signiﬁcantly
Table 2 Comparison of the age, clinical manifestations, laboratory investigations, renal biopsy class and disease activity grades
among 3 STAT4 genotypes in SLE patients.
Feature STAT4 genotype in SLE patients (n= 65) p
GG (n= 40) GT (n= 21) TT (n= 4)
Age 30.85 ± 9.36 27.19 ± 8.29 23.5 ± 5.45 0.14
Clinical manifestations
Fever 20 (50) 10 (47.62) 2 (50) 0.99
Myalgia 10 (25) 2 (9.52) 1 (25) 0.36
Muco cutaneous Malar rash 36 (90) 17 (80.95) 2 (50) 0.09
Photosensitivity 18 (45) 7 (33.33) 2 (50) 0.65
Alopecia 25 (62.5) 15 (71.43) 2 (50) 0.59
Oral ulcers 21 (52.5) 10 (47.62) 2 (50) 0.94
Arthritis 35 (87.5) 20 (95.24) 4 (100) 0.51
Vasculitis 7 (17.5) 1 (4.76) 1 (25) 0.32
Pleurisy 21 (52.5) 10 (47.62) 2 (50) 0.94
Lupus cerebritis Lupus headache 5 (12.5) 0 (0) 0 (0) 0.19
Seizures 3 (7.5) 0 (0) 1 (25) 0.14
Psychosis 5 (12.5) 1 (4.76) 0 (0) 0.51
Laboratory investigations
ESR (mm/1st hr) 79.58 ± 39 75.76 ± 44.95 66.25 ± 34.97 0.8
Hb (g/dl) 9.82 ± 1.99 9.59 ± 2.73 10.78 ± 2.36 0.64
TLC (·103/cm3) 8.18 ± 5.24 5.67 ± 2.78 8.78 ± 3.42 0.11
Platelets (·103/cm3) 324.1 ± 142.8 278.8 ± 118.2 199.75 ± 69.7 0.14
Creatinine (mg/dl) 0.99 ± 0.63 0.96 ± 1.03 0.8 ± 0.34 0.89
Urea (mg/dl) 43.18 ± 28.8 55.05 ± 49.02 49.75 ± 38.9 0.49
C3 (mg/dl) 53.19 ± 36.6 49.08 ± 40.07 0.56 ± 0.2 0.17
C4 (mg/dl) 14.83 ± 25.9 8.7 ± 12.2 0.17 ± 0.04 0.53
Albuminuria N (%) 29 (72.5) 15 (71.43) 4 (100) 0.12
Grade 3+ 13 (32.5) 0 (0) 2 (50) –
2+ 7 (17.5) 9 (42.86) 1 (25) –
1+ 9 (22.5) 6 (28.57) 1 (25) –
Nil 11(27.5) 6 (28.57) 0 (0) –
ANA positivity 39 (97.5) 20 (95.24) 4 (100) 0.84
Anti-ds DNA 30 (75) 17 (80.95) 4 (100) 0.5
Renal biopsy and LN (N = 20) 0.63
Class II 3 (7.5) 2 (9.5) 1 (25)
III 5 (12.5) 2 (9.5) –
IV 3 (7.5) 1 (4.8) 1 (25)
V 2 (5) – –
SLEDAI grade 0.63
Grade Mild (<8) 12 (30) 5 (23.8) 1 (25)
Moderate (8–18) 14 (35) 14 (66.7) 2 (50)
Severe (>18) 14 (35) 2 (9.5) 1 (25)
Results are presented as mean ± SD or N (%). STAT4: signal transducer and activator of transcription 4; ESR: erythrocyte sedimentation rate;
Hb: hemoglobin; TLC: total leukocytic count; C: complement; DNA: deoxyribonucleic acid; LN: lupus nephritis; SLEDAI: systemic lupus
erythematosus disease activity index.
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romutant genotype. Lupus nephritis (LN) is one of the most
serious SLE complications since it is a major predictor of poor
prognosis. It is a major concern as it affects approximately
50% of the patients and accounts for signiﬁcant morbidity
and mortality [29]. Our results go with those previously
reported by Kawasaki et al. [26] as lupus nephritis was higher
in SLE patients with STAT4 polymorphic alleles. Genetic vari-
ations in STAT4 predispose to lupus nephritis and a worse
outcome with severe renal insufﬁciency [30]. The clinical man-
ifestations and disease severity vary greatly among patients,
thus several studies try to associate clinical heterogeneity and
prognosis with speciﬁc genetic polymorphisms in SLEassociated genes. The continuous effort to describe new predis-
posing or modulating genes in SLE is justiﬁed by the limited
knowledge about pathogenesis, assorted clinical manifestation
and possible prevention strategies [11].
The TLC was signiﬁcantly lower in SLE patients with the
GT genotype compared to the count in those with GG geno-
types. The C3 and C4 levels in SLE patients with the TT geno-
type were signiﬁcantly consumed compared to those with GG
and GT genotypes. It was reported that complement activation
and sublytic C5b-9 assembly on the plasma membrane were
able to activate STAT4 in endothelial cells [31].
In our study, those with the TT genotype had a signiﬁcantly
higher anti-ds DNA positivity compared to those with GG and
STAT4 G/T gene polymorphism 79GT genotypes. Anti-dsDNA antibodies are signiﬁcant predic-
tors of LN [32]. Kawasaki et al. [26] reported that anti-DNA
antibodies were higher in SLE patients with STAT4 polymor-
phism. It has been reported that STAT4 polymorphisms are
associated with autoimmune diseases which are characterized
by a systemic pathology and anti-dsDNA antibody [33]. The
rs7574865 SNP in STAT4 has been associated with a severe
SLE phenotype deﬁned not only with the immunologic disor-
der (speciﬁcally, ds-DNA autoantibodies) but also with
nephritis and age at diagnosis <30 years old [23].
The STAT4 genotype in the juvenile onset SLE cases
tended to show a higher GT (50%) and TT (12.5%) polymor-
phism compared to that in the adult onset cases as GT was
present in 29.8% and TT in 5.3%. It was reported that the
prevalence of damage was increased in juvenile-onset SLE
Egyptian patients compared to adult-onset ones [34] .Kawasa-
ki and Colleagues [26] reported that STAT4 polymorphism
was higher in SLE Japanese patients with an age of onset of
less than 20 years. Associations of polymorphisms in STAT4
with childhood-onset SLE were conﬁrmed in another Japanese
population. The cumulative number of risk alleles was signiﬁ-
cantly increased in childhood-onset cases [35].
In conclusion, in the present study STAT4 (G/T rs7574865)
polymorphism was not associated with an increased risk of
SLE in Egyptian females. An increased frequency of vasculitis,
photosensitivity and renal involvement was present among
SLE patients harboring homomutant genotypes, raising the
possibility that genetic polymorphism may be an important
determinant affecting disease progression. Genetic polymor-
phism of STAT4 (TT) was associated with an increased com-
plement consumption and anti-DNA positivity compared to
other genotypic alleles. Larger studies are required to elucidate
the relevance of STAT4 polymorphism in the susceptibility to
systemic lupus and its impact on the clinical and laboratory
features of the disease.
Conﬂict of interest
All authors declare that they have no conﬂict of interest.
Disclosures
None.
References
[1] Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM,
Guthridge JM, et al. Role of MYH9 and APOL1 in African and
non African populations with lupus nephritis. Genes Immun
2012;13(3):232–8.
[2] Bae SC, Fraser P, Liang MH. The epidemiology of systemic lupus
erythematosus in populations of African ancestry: a critical review
of the ‘‘prevalence gradient hypothesis’’. Arthritis Rheum
1998;41(112):2091–9.
[3] Hart HH, Grigor RR, Caughey DE. Ethnic difference in the
prevalence of systemic lupus erythematosus. Ann Rheum Dis
1983;42(5):529–32.
[4] Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demo-
graphic differences in the development of lupus nephritis: a
retrospective analysis. Am J Med 2002;112:726–9.
[5] Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of
systemic lupus erythematosus. Springer Semin Immunopathol
2006;28:119–30.[6] Delgado-Vega A, Sa´nchez E, Lo¨fgren S, Castillejo-Lo´pez C,
Alarco´n-Riquelme ME. Recent ﬁndings on genetics of systemic
autoimmune diseases. Curr Opin Immunol 2010;22:698–705.
[7] Warcho T, Lianeri M, acki JK, Jagodzin´ski PP. SDF1-30 G801A
polymorphisms in Polish patients with systemic lupus erythema-
tosus. Mol Biol Rep 2010;37:3121–5.
[8] Jo¨nsen A, Bengtsson AA, Nived O, Truedsson L, Sturfelt G.
Gene–environment interactions in the aetiology of systemic lupus
erythematosus. Autoimmunity 2007;40:613–7.
[9] Crispı´n JC, Tsokos GC. Novel molecular targets in the treatment
of systemic lupus erythematosus. Autoimmun Rev 2008;7:256–61.
[10] Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA.
Genetic susceptibility to SLE: new insights from ﬁne mapping and
genome-wide association studies. Nat Rev Genet 2009;10:285–90.
[11] De Azevedo Silva J, Addobbati C, Sandrin-Garcia P, Crovella S.
Systemic lupus erythematosus: old and new susceptibility genes
versus clinical manifestations. Curr Genomics 2014;15(1):52–65.
[12] Wang C, Sandling JK, Hagberg N, Berggren O, Sigurdsson S,
Karlberg O, et al. Genome-wide proﬁling of target genes for the
systemic lupus erythematosus-associated transcription factors
IRF5 and STAT4. Ann Rheum Dis 2013;72(1):96–103.
[13] Pascual V, Farkas L, Banchereau J. Systemic lupus erythemato-
sus. All roads lead to type 1 interferons. Curr Opin 2006;18:
676–82.
[14] Abelson AK, Delgado-Vega AM, Kozyrev SV, Sa´nchez E,
Vela´zquez-Cruz R, Eriksson N, et al. STAT4 associates with
systemic lupus erythematosus through two independent effects
that correlate with gene expression and act additively with IRF5
to increase risk. Ann Rheum Dis 2009;68:1746–53.
[15] Luan H, Li P, Cao C, Li C, Hu C, Zhang S, et al. A single-
nucleotide polymorphism of the STAT4 gene is associated with
systemic lupus erythematosus (SLE) in female Chinese popula-
tion. Rheumatol Int 2012;32(5):1251–5.
[16] Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S,
et al. STAT4 is expressed in activated peripheral blood mono-
cytes, dendritic cells, and macrophages at sites of Th1-mediated
inﬂammation. J Immunol 2000;164:4659–64.
[17] Jacob CO, Zang S, Li L, Ciabanu V, Quismorio F, Mizutani A,
et al. Pivotal role of STAT4 and STAT6 in the pathogenesis of
lupus like disease in the New Zealand mixed 2328 mice. J
Immunol 2003;171:1564–71.
[18] Murphy KM, Reiner SL. The lineage decisions of helper T cells.
Nat Rev Immunol 2002;2:933–44.
[19] Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q,
O’Malley JT, et al. STAT3 and STAT 4 direct development of IL-
17-secreting Th cells. J Immunol 2003;178:4901–7.
[20] Petri M, Orbai AM, Alarco´n GS, Gordon C, Merrill JT, Fortin
PR, et al. Derivation and validation of the Systemic Lupus
International Collaborating Clinics classiﬁcation criteria for
systemic lupus erythematosus. Arthritis Rheum 2012;64(8):
2677–86.
[21] Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.
Derivation of the SLEDAI: a disease activity index for lupus
patients, The Committee on Prognosis Studies in SLE. Arthritis
Rheum 1992;35:630.
[22] Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM,
Bauer JW, et al. Argentine and Spanish Collaborative Groups. A
common haplotype of interferon regulatory factor 5 (IRF5)
regulates splicing and expression and is associated with increased
risk of systemic lupus erythematosus. Nat Genet 2006;38:550–5.
[23] Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM,
Tian C, et al. Speciﬁcity of the STAT4 genetic association for
severe disease manifestations of SLE. PLoS Genet 2008;4(5):
e1000084.
[24] Piotrowski P, Lianeri M, Wudarski M, Olesin´ska M, Jagodzin´ski
P. Contribution of STAT4 gene single-nucleotide polymorphism
to systemic lupus erythematosus in the Polish population. Mol
Biol Rep 2012;39:8861–6.
80 I.I. Raafat et al.[25] Li P, Cao C, Luan H, Li C, Hu C, Zhang S, et al. Association of
genetic variations in the STAT4 and IRF7/KIAA1542 regions
with systemic lupus erythematosus in a Northern Han Chinese
population. Hum Immunol 2011;72:249–55.
[26] Kawasaki A, Kyogoku C, Ohashi J, Miyashita R, Hikami K,
Kusaoi M. Association of IRF5 polymorphisms with systemic
lupus erythematosus in a Japanese population: support for a
crucial role of intron 1 polymorphisms. Arthritis Rheum
2008;58:826–34.
[27] Zervou MI, Vazgiourakis VM, Yilmaz N, Kontaki E, Trouw LA,
Toes RE, et al. TRAF1/C5, eNOS, C1q, but not STAT4 and
PTPN22 gene polymorphisms are associated with genetic suscep-
tibility to systemic lupus erythematosus in Turkey. Hum Immunol
2011;72:1210–3.
[28] Yang W, Ng P, Zhao M, Hirankarn N, Lau CS, Mok CC, et al.
Population differences in SLE susceptibility genes: STAT4 and
BLK, but not PXK, are associated with systemic lupus erythe-
matosus in Hong Kong Chinese. Genes Immun 2009;10:219–26.
[29] Kobert SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J,
Rohde RD. For the Lupus Nephritis Collaborative Study Group.
Factors predictive of outcome in severe lupus nephritis. Am J
Kidney Dis 2000;35:904–14.[30] Bolin K, Sandling JK, Zickert A, Jo¨nsen A, Sjo¨wall C,
Svenungsson E, et al. Association of STAT4 polymorphism with
severe renal insufﬁciency in lupus nephritis. PLoS One
2013;8(12):e84450.
[31] Niculescu F, Rus H. Complement activation and atherosclerosis.
Mol Immunol 1999;36(13–14):949–55.
[32] Bastian HM, Roseman JM, McGwin Jr G, Alarco´n GS, Fried-
man AW, Fessler BJ, et al. Systemic lupus erythematosus in three
ethnic groups. XII. Risk factors for lupus nephritis after diagno-
sis. Lupus 2002;11(3):152–60.
[33] Zheng J, Yin J, Huang R, Petersen F, Yu X. Meta-analysis reveals
an association of STAT4 polymorphisms with systemic autoim-
mune disorders and anti-dsDNA antibody. Hum Immunol
2013;74(8):986–92.
[34] Gheita TA, Fawzy SM, Nour El-din AM, El-Fishawy HS.
Juvenile and adult onset systemic lupus erythematosus outcome
in Egyptian patients. Egypt Rheumatol 2011;33:99–105.
[35] Kadota K, Mori M, Yanagimachi M, Miyamae T, Hara T,
Kanetaka T, et al. Analysis of gender differences in genetic risk:
association of TNFAIP3 polymorphism with male childhood-
onset systemic lupus erythematosus in the Japanese population.
PLoS ONE 2013;8(8):e72551.
